Founded in 2006, Windham is a New York City based venture capital firm focused on healthcare, with a particular emphasis on medical technology (devices and diagnostics) and digital health (the intersection of biology, genomics, and information technology).   Windham seeks to invest in and partner with companies that are commercializing game-changing technologies to serve unmet needs in order to improve the lives of large numbers of patients and yield robust returns for its investors.   For more information visit: www.windhamvp.com

Windham Venture Partners

Merck Global Health Innovation Fund (Merck GHI) is evolving corporate healthcare venture capital globally by utilizing their healthcare ecosystem strategy.  This investment strategy connects innovative companies with complementary technologies to develop integrated healthcare solutions.  Merck GHI has $500M under management and provides growth capital to emerging healthcare technology companies worldwide while leveraging the vast R&D-based, global resources of Merck.  With a vision that data will be the currency in healthcare, GHI invests broadly in digital health.  GHI invests in platform companies with proven technologies or business models where Merck's expertise and perspectives can accelerate revenue growth and enhance value creation.   Since late 2010, Merck GHI has made over 20 investments in Digital Health companies.

Merck Global Health Innovation Fund

TCP Venture Capital was founded by Christopher College and Stuart Sutley in November 2012. It is based in Baltimore, Maryland.

TCP Venture Capital

The primary responsibilities of the group are to source, qualify, and invest in technology related companies. Our major investment areas include semiconductors, materials, mobile service, internet, software, security, enterprise solutions, bio engineering & medical, while potential investment subjects range from early-stage startups to pre-IPO companies. Currently, the group has over $1.8B under management and invests $250M annually.  Samsung Ventures was founded on October 8, 1999, and is based in Seoul, South Korea.

Samsung Ventures

Adage Capital Management is a Boston-based $8.9B Money Management firm focused on managing S&P 500 assets predominantly for Endowments and Foundations such as Harvard University, Northwestern University, Dartmouth College, the American Red Cross and the Getty Foundation. Adage and its predecessor, the Select Equity Group at the Harvard Management Company, has outperformed the S&P index in each of the last 15 years by an average of 3.5%.   The fund is run by Phill Gross, who prior to founding Adage, was a Healthcare and Retail analyst, equity research director and partner at the Harvard Management Company for 18 years..

Adage Capital Management

Excel Venture Management builds companies that apply transformative life science technologies to solve problems in healthcare and beyond. The Excel investment portfolio is balanced across healthcare IT and services, diagnostics, and medical devices, plus life science platforms that address adjacent markets including energy, chemicals, defense and agriculture.  The majority of the teamâ€™s prior investments, which include some of the worldâ€™s premier healthcare and life science companies, are thriving and over half have achieved successful exits generating billions in value.  Excel Venture Management is a spin-off of CB Health Ventures.

Excel Venture Management

AMV is a venture capital firm investing in early-stage digital health, tech, and life sciences companies. The firm has provided early-stage financing for ground-breaking companies such as Amgen, Tandem Computer, and Applied BioSystems. Asset Management was founded in 1965 by venture capitalist Franklin ''Pitch'' Johnson in Palo Alto, California.

Asset Management Ventures (AMV)

Alexandria Venture Investments is a strategic venture capital arm of Alexandria Real Estate Equities. Alexandria Venture Investments provides long-term strategic investment capital to innovative life science and technology entities developing breakthrough technologies and therapies.  Leveraging their experience and in-depth understanding of the life science and technology industries, their long-term relationships with leading investors, and their world-class scientific advisory network, they  are uniquely positioned to fund seed-, early-, and growth-stage companies.

Alexandria

Hudson River Capital Parnters, through its investment arm, Hudriv Investments LLC,  is a small-cap, private investment firm focused on healthcare businesses, both services and products, headquartered in Westchester County, NY. Hudriv was formed by James Foy and Clay Lifflander to invest in companies which add value to the health care system and have the potential to be financially successful. We will look at both minority and control positions, via angel investment for existing young companies, start-ups and acquisition of operating companies with the potential for growth.

Hudson River Capital Partners

Johnson & Johnson Innovation is a center for science and business experts to collaborate with innovators to incorporate science into healthcare solutions, including medical device and diagnostic technologies, consumer healthcare products, and pharmaceuticals. It is focused on the advancement of new healthcare solutions in the consumer, pharmaceutical, and medical devices and diagnostics sectors.’ The company provides financing tools that include early-stage research funding, seed funding, equity investments, licensing, and collaborations. Additionally, it offers its partners access to international markets, pricing and reimbursement, market testing, company creation services, and more. They conduct their activities with the help of regional incubators, satellite operations, single bench tops, modular labs, office space for entrepreneurs, and a year-round curriculum focused on business and drug development. Johnson & Johnson Innovation is a subsidiary of [Johnson & Johnson](http://www.crunchbase.com/organization/johnson-johnson)  and its centers are located in Boston, California, London, and Shanghai.

Johnson & Johnson Robotics and Digital Solutions

Welldoc

Welldoc develops technology solutions to support chronic disease management. They work with leaders across the healthcare, life science, and medical device industries to ensure the solutions they develop scale and integrate into their existing workflows and systems. The Welldoc platform offers support for multiple chronic conditions, ecosystem solutions, and artificial intelligence.

Welldoc offers a chronic care platform supporting various conditions such as prediabetes, diabetes, hypertension, heart failure, weight management, mental well-being, and sleep apnea. Welldoc's FDA-cleared digital health app, BlueStar, assists individuals in self-managing their diabetes care and strengthens their connections with their healthcare team. The company offers holistic guidance to assist individuals in managing their daily nutrition, physical activity, data tracking, and long-term trends.

Membership-based, non-insurance healthcare companies helping maintain a steady state of well being.

Preventive Healthcare

Welldoc Announces Collaboration to Support Cardiometabolic Health by Integrating AI-Driven Digital Coaching with ...

Eli Lilly

Welldoc and Eli Lilly collaborate to integrate insulin management software.

Platforms offer a subscription-based or B2B-sponsored, evidence-based program for managing a specific long-term health condition.

Welldoc offers a chronic care platform supporting various conditions such as prediabetes, diabetes, hypertension, heart failure, weight management, mental well-being, and sleep apnea. Welldoc's FDA-cleared digital health app, BlueStar, assists individuals in self-managing their diabetes care and strengthens their connections with their healthcare team. The company offers holistic guidance to assist individuals in managing their daily nutrition, physical activity, data tracking, and long-term trends.In August 2023, the company was the first to receive FDA approval to provide bolus insulin dose recommendations based on continuous glucose monitoring (CGM) readings, and, as of May 2024, the company held 11 FDA clearances and 43 patents for advanced AI and technology and was included in more than 80 clinical publications.&nbsp;Key customers and partnershipsTo expand its solutions, the company has partnered with pharmacy benefit managers, health plans, health systems, and employers, including 1) Dexcom, provider of a CGM system, to offer integrated type 2 diabetes management solutions (in April 2021), 2) LifeScan, a blood glucose monitoring provider, to incorporate Welldoc’s platform into LifeScan’s OneTouch Solutions for diabetes management (in September 2021), and 3) Conifer Health Solutions, a Johnson &amp; Johnson company producing blood glucose meters, to launch a health app called Conifer Connect (in April 2023).Funding and financialsIn March 2016, the company raised USD 29.5 million in a Series B round led by Samsung Ventures, Johnson &amp; Johnson Robotics, and Digital Solutions. The funds were used for commercialization of its BlueStar solution.

Welldoc offers a chronic care platform supporting various conditions such as prediabetes, diabetes, hypertension, heart failure, weight management, mental well-being, and sleep apnea. Welldoc's FDA-cleared digital health app, BlueStar, assists individuals in self-managing their diabetes care and strengthens their connections with their healthcare team. The company offers holistic guidance to assist individuals in managing their daily nutrition, physical activity, data tracking, and long-term trends.In August 2023, the company was the first to receive FDA approval to provide bolus insulin dose recommendations based on continuous glucose monitoring (CGM) readings, and, as of May 2024, the company held 11 FDA clearances and 43 patents for advanced AI and technology and was included in more than 80 clinical publications.Key customers and partnershipsTo expand its solutions, the company has partnered with pharmacy benefit managers, health plans, health systems, and employers, including 1) Dexcom, provider of a CGM system, to offer integrated type 2 diabetes management solutions (in April 2021), 2) LifeScan, a blood glucose monitoring provider, to incorporate Welldoc’s platform into LifeScan’s OneTouch Solutions for diabetes management (in September 2021), and 3) Conifer Health Solutions, a Johnson &amp; Johnson company producing blood glucose meters, to launch a health app called Conifer Connect (in April 2023).Funding and financialsIn March 2016, the company raised USD 29.5 million in a Series B round led by Samsung Ventures, Johnson &amp; Johnson Robotics, and Digital Solutions. The funds were used for commercialization of its BlueStar solution.

Cardiomo Care is developing noninvasive wearable devices to alert users and caretakers when there are abnormalities in the heartbeat. The company’s AI engine, trained on existing and growing data sets, can predict potential heart issues up to two hours before they occur, enabling early detection and intervention for arrhythmias and other cardiovascular diseases (CVDs).The company's product, CardiomoPatch, is a waterproof, wearable patch capable of long-term wear with a 10-day battery life. The patch monitors a patient's cardiac data, including ECG outputs, breathing, and skin temperature, and transmits the data via a mobile app for analysis by Cardiomo's AI engine.&nbsp;As of May 2024, the company is yet to commercialize its product and has over 1,600 pre-orders.

Cardiomo Care

Omada is a prevention-focused digital therapeutics startup that helps members achieve health goals through lifestyle changes. It offers four evidence-based, virtual prevention programs for managing hypertension, musculoskeletal (MSK) issues, prediabetes, and diabetes.Omada offers real-time data tracking through connected devices (such as wireless scales, blood pressure, and glucose monitors) and access to personalized coaching sessions via a mobile app as part of its prevention program. It also provides an online community of peers with similar health conditions to discuss challenges and provide support. In May 2021, Omada became the first fully-virtual healthcare provider to earn the National Committee for Quality Assurance’s Population Health Program Accreditation for its type 2 diabetes and type 2 diabetes + hypertension programs.Unlike its peers, Omada operates a performance-based business model where it charges clients an enrollment fee based on the number of users and a performance fee based on how much weight their employees lose. In May 2020, the company acquired virtual physical therapy startup Physera.Key customers and partnershipsAs of May 2024, Omada had more than 1 million members from more than 1,900 enterprise clients across all 50 US states. Its B2B employer and health plan client base include key clients such as American Eagle, Kaiser Permanente, Costco Wholesale, 3M, and Marvin. Additionally, the company has partnered with health systems and hospitals such as Intermountain Healthcare to provide its preventive programs as a covered benefit.In <a href="https://sp-edge.com/updates/15587">January 2023</a>, the company partnered with health service company Castell (a subsidiary of Intermountain Healthcare) to provide its diabetes programs to members from Intermountain Healthcare’s primary care providers in its Utah Medical Group. Further in <a href="https://sp-edge.com/updates/25245">January 2024</a>, the company partnered with Amazon to expand access to its cardiometabolic program.

Omada Health

VillageMD provides primary care services for patients. It also provides tools, technology, and staffing support needed for physicians to deliver high-quality services. VillageMD’s service delivery methods include traditional freestanding clinics, Village Medical at Walgreens co-located clinics, as well as at-home and around-the-clock virtual visits. It also leverages a team-based approach to care where physicians lead nurse practitioners, pharmacists, mental health specialists, and dietitians to offer a holistic care program. The technology of VillageMD includes docOS, an operating system that enables better patient care by connecting various clinical source systems with ongoing patient-generated data coupled with an AI engine to continuously analyze messages to enable patient self-care.The company made several acquisitions to expand its footprint: 1) <a href="https://sp-edge.com/updates/14347">Summit Health</a> for USD 8.9 billion in November 2022, 2) Healthy Interactions, an interactive patient education platform, in February 2022, and 3) <a href="https://sp-edge.com/updates/16968">Starling Physicians</a>, a primary care and specialty care provider, in March 2023.Key customers and partnershipsIn June 2020, VillageMD and Walgreens Boots Alliance announced a collaborative effort to open at least 600 Village Medical centers at Walgreens across more than 30 US markets by 2025. Walgreens invested USD 5.2 billion in VillageMD (from the previously announced USD 1.0 billion), raising its ownership stake to 63% (from 30%).However, as of May 2024, Walgreens had plans to close 160 VillageMD clinics as part of a cost-cutting plan.

VillageMD

Cityblock Health is a value-based healthcare provider focused on delivering comprehensive care to underserved communities, primarily Medicaid and lower-income Medicare beneficiaries. The company combines primary care, behavioral health, and social services to address the complex physical, mental, and social needs of its members.Cityblock's model involves partnering with local community-based organizations and deploying multidisciplinary care teams that include doctors, nurses, behavioral health specialists, and community health workers. These teams provide personalized care through 24/7 access to multi-modal care delivery, including in-home visits, telehealth, and community health hubs.The services of Cityblock are available to members at no additional cost if they are covered by an eligible health plan.Key Customers and PartnershipsAs of May 2024, the company’s services were available in seven states across the US and served over 100,000 members.In May 2024, it partnered with <a href="https://sp-edge.com/updates/29647">Sunshine Health</a> to expand to Florida, and, in <a href="https://sp-edge.com/updates/13270">September 2022</a>, it partnered with MDwise to expand into Indiana. Prior to that, the company had partnered with insurance providers such as ConnectiCare (Connecticut), Tufts Health Plan (Massachusetts), Emblem Health (New York), Healthy Blue (North Carolina), Molina Healthcare (Ohio) and CareFirst (Washington DC).Funding and FinancialsCityblock is a spin-off of Sidewalk Labs, an Alphabet company that incubates and invests in tech companies and products to improve urban infrastructure. It completed a USD 400 million Series D funding round led by Softbank in <a href="https://sp-edge.com/updates/5326">September 2021</a>, valuing the company at USD 5.7 billion. The funds were used to expand its services.

Cityblock Health

Everside Health (formerly Paladina Health) offers preventative care for chronic conditions and primary, mental and occupational healthcare treatments for acute conditions. Patients benefit from around-the-clock access to care, same-day or next-day appointments for in-person, and virtual care visits with zero copays.Everside aims to generate around 17% healthcare cost savings in three years and 31% in five years for its corporate members by leveraging a data-driven approach to care coordination.The company leverages data from past medical records, predictive analytics, and AI in the delivery of preventative care services.Founded in 2010 under the name Paladina Health, the company was rebranded in November 2020 as Everside Health following a merger between three primary care groups (Paladina, Activate Healthcare, and Healthstat). Furthermore, in February 2024, Everside Health merged with primary care provider Marathon Health to form a combined entity that would operate as Marathon Health, and, as of May 2024, the integration was ongoing.Key customers and partnershipPost-merger with Marathon Health, the combined entity would serve 2.5 million patients through over 680 clinics across 41 states.Funding and financialsThe company received its most recent investment in July 2022, amounting to USD 164 million in growth equity funding. The round was led by New Enterprise Associates (NEA). The funds were allocated toward growing its market presence and exploring opportunities for M&amp;A as well as to enhance and improve its product features. Additionally, the firm planned to expand its coverage of specialty care services aimed at individuals, employers, and union organizations.

Everside Health

DPCs offer value-based primary and preventive care services addressing whole-person (social, mental, physical) needs for a fixed monthly or annual fee paid by either the patient, insurance provider, or employer.

Companies offer B2B and D2C evidence-based treatments delivered via software programs to prevent and manage a variety of chronic conditions.

Tools that collect and analyze real-time patient data that supports healthcare providers with clinical decisions,  improves patient outcomes, and reduces medical errors.

Companies offer independent physician practices and hospitals with the tools (patient engagement, care coordination, administrative services) to help manage and improve clinical health outcomes of a defined group of individuals or large populations.

Platforms are used to track and gather patient health-related information via either a connected device or at-home test kits to detect the early onset of disease and identify any abnormalities in readings—but do not include a treatment plan.

To gather large amounts of real-time data for chronic care management, DTx, and patient monitoring

XR used by some startups for chronic pain management

Offers digital means of providing direct primary care, passive remote monitoring, chronic care management, etc.

AI/ML is used in predictive analytics, diagnostics tools, and population management

Offers tailored preventive interventions and treatments to the specific needs and characteristics of each individual

More important now than ever, telehealth will long outlast the pandemic that drove its growth.

Telehealth

DISRUPTOR_PRESENT

PROMINENT_CATEGORY

Evernorth, the pharmacy care and health benefits arm of Cigna, has acquired Bright.md through its subsidiary, MDLive. MDLive plans to incorporate Bright.md's offerings into its virtual care platform, with an emergency asynchronous option for virtual urgent care launching in 2024. The company also has plans to expand these care options into chronic disease management services and wellness visits. Additionally, MDLive will expand its chronic condition care management services to include health coaching, powered by AI-based digital coaching provider Welldoc. This will allow providers to engage patients and support them in managing lifestyle changes.

Welldoc

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless